RE:Normally we have a 20% drop! We saw the same market reaction after last Q report. Drop day of report, then slow upward move days and weeks that followed. The results indicate a very high efficacy signal and high safety. They also indicate that patients treated with the Optimized Procedure ( patients treated after 1st set of 12 severely undertreated) are showing very high efficacy as expected. The FDA will see the detailed data on every single patient which PI's are preparing now for BTD application. It will be even more clear to them that the Optimized Treatment procedure is producing the desired and predictable high efficacy and safety we all hoped for initially. I personally think we could end up with 50-60% CR or better at 450 days, at least well over the 30% benchmark. All IMHO
Lesalpes29 wrote: After a quaterly report... I can live with a minus 2%.